Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II Clinical study of TARA-002 in pediatric Lymphatic Malformations patients

Next Previous
Trial Profile

A phase II Clinical study of TARA-002 in pediatric Lymphatic Malformations patients

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Picibanil (Primary)
  • Indications Lymphangioma
  • Focus Adverse reactions; Registrational

Most Recent Events

  • 05 Mar 2025 According to a Protara Therapeutics media release, the Company expects to provide an update on the design of its planned BCG-Naive registrational trial by the end of the first half of 2025.
  • 08 Mar 2023 According to a Protara Therapeutics media release, trial initiation expected in 2H23
  • 03 Nov 2022 According to a Protara Therapeutics media release, the company has received initial feedback from the Vaccines and Related Products Division of the FDA on the protocol for the trial and the company is in process of finalizing the trial design.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top